Direct-Acting Antiviral Medicines Market size is likely to register remarkable growth rate during the forecast period i.e., between 2024-2036.
Increasing prevalence of liver cirrhosis and hepatocellular carcinoma, along with the growing investment in the development of advanced therapies are expected to fuel the progress of this market. The growth of the market can also be attributed to factors such as increase in awareness for treatment and improvement in healthcare infrastructure in developing countries. According to the World Health Organization (WHO), nearly 71 million people are living with chronic hepatitis C virus infection. Of these, a large group of population developed cirrhosis or liver cancer.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
Regional Scope |
|
The market is segmented based on drug class into NS3/4A protease inhibitors, NS5A polymerase inhibitors, NS5B polymerase inhibitors, and combination drugs, out of which, the combination drugs segment is anticipated to grab the largest share by the end of 2021 on account of being evaluated as suitable medicine for treatment of liver diseases in a large number of clinical trials. Moreover, there is a significant growth in investment on these trials, which is also projected to contribute to the growth of the segment during the forecast period.
On the basis of end-user, the hospital pharmacies segment in the direct-acting antiviral medicines market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that more patients choose hospitals as their treatment option and there is an increased availability of prescribed antiviral medicines at hospital pharmacies.
Our in-depth analysis of the global market includes the following segments
|
By Drug Class Type |
|
|
By End-User |
|
APAC Market Statistics
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. Asia Pacific industry is likely to account for largest revenue share by 2036, owing to increasing hepatitis C infection prevalence and rising focus of major companies for expanding their product to countries in the region.
North America Market Analysis
Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to high awareness about direct-acting antiviral medicines in the region, accompanied by the presence of leading healthcare service providers in the region. Along with this, the North America also leads in terms of reimbursement policy system, which is also expected to contribute to the market growth in the region.
Europe Market Analysis
Alternatively, the market in Europe is also anticipated to occupy a significant share in the direct-acting antiviral medicines market on account of increase in number of patients with hepatitis C infection & lung cancer along with presence of large pharmaceutical companies. As per the analysis of World Health Organization, Europe is one of the most affected region by Hepatitis C infection, where approximately 14 million people are chronically infected with Hepatitis C, leading to about 112,500 deaths per year from Hepatitis C-related liver cancer and cirrhosis.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?